High glucose and insulin differentially modulates proliferation in MCF-7 and MDA-MB-231 cells

Journal of Molecular Endocrinology

Volumn 51, Issue 1, 2013, Pages 119-129

  Gupta, Chanchal ^a   Tikoo, Kulbhushan ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Cell proliferation; High glucose; Histone H3 modifications; Insulin

Indexed keywords

CYCLIN D1; GLUCOSE; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; REACTIVE OXYGEN METABOLITE;

ACETYLATION; ARTICLE; BREAST CANCER; BREAST METASTASIS; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DEPHOSPHORYLATION; EARLY RESPONSE GENE; EXTRACELLULAR MATRIX; GLUCOSE BLOOD LEVEL; GLYCOGEN SYNTHESIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN TREATMENT; INTRACELLULAR SIGNALING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CELL PROLIFERATION; HIGH GLUCOSE; HISTONE H3 MODIFICATIONS; INSULIN;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; HISTONES; HUMANS; INSULIN; MCF-7 CELLS; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; REACTIVE OXYGEN SPECIES;

EID: 84879963666     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-13-0062     Document Type: Article

References (73)

1. Alao JP 2007 The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Molecular Cancer 6 24. (doi:10.1186/1476-4598-6-24)
2. Anh TD, Ahn MY, Kim SA, Yoon JH & Ahn SG 2012 The histone deacetylase inhibitor, trichostatin A, induces G2/M phase. Oncology Reports 27 455-460. (doi:10.3892/or.2011.1496)
3. Beckner ME, Stracke ML, Liotta LA & Schiffmann E 1990 Glycolysis as primary energy source in tumor cell chemotaxis. Journal of the National Cancer Institute 82 1836-1840. (doi:10.1093/jnci/82.23.1836)
4. Behrend L, Henderson G & Zwacka RM 2003 Reactive oxygen species in oncogenic transformation. Biochemical Society Transactions 31 1441-1444. (doi:10.1042/BST0311441)
5. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J & Rivard N 2000 MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. Journal of Cellular Biochemistry 79 355-369. (doi:10.1002/1097-4644(20001201)79:3!355::AID-JCB20O3.0.CO;2-0)
6. Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, Fairley LL, Zheng T, Zhang Y, Pasterk M et al. 2012 Diabetes and breast cancer risk: a meta-analysis. British Journal of Cancer 107 1608-1617. (doi:10.1038/bjc.2012.414)
7. Burdon RH 1995 Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radical Biology & Medicine 18 775-794. (doi:10.1016/0891-5849(94)00198-S)
8. Chakrabarti S & Davidge ST 2009 High glucose-induced oxidative stress alters estrogen effects on ERa and ERb in human endothelial cells: reversal by AMPK activator. Journal of Steroid Biochemistry and Molecular Biology 117 99-106. (doi:10.1016/j.jsbmb.2009.07.007)
9. Chen F & Castranova V 2007 Nuclear factor-kB, an unappreciated tumor suppressor. Cancer Research 67 11093-11098. (doi:10.1158/0008-5472. CAN-07-1576)
10. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, Wright A, Vanderbilt C & Cobb MH 2001 MAP kinases. Chemical Reviews 101 2449-2476. (doi:10.1021/cr000241p)
11. Choi HS, Choi BY, Cho YY, Mizuno H, Kang BS, Bode AM & Dong Z 2005 Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. Cancer Research 65 5818-5827. (doi:10.1158/0008-5472.CAN-05-0197)
12. Coebergh JW, Janssen-Heijnen ML, Post PN & Razenberg PP 1999 Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. Journal of Clinical Epidemiology 52 1131-1136. (doi:10.1016/S0895-4356(99)00098-0)
13. Czyzyk A & Szczepanik Z 2000 Diabetes mellitus and cancer. European Journal of Internal Medicine 11 245-252. (doi:10.1016/S0953-6205(00)00106-0)
14. Eldar-Finkelman H, Schreyer SA, Shinohara MM, LeBoeuf RC & Krebs EG 1999 Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes 48 1662-1666. (doi:10.2337/ diabetes.48.8.1662)
15. Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR & Mills GB 2000 Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. PNAS 97 11960-11965. (doi:10.1073/pnas. 220413597)
16. Ferguson RD, Novosyadlyy R, Fierz Y, Alikhani N, Sun H, Yakar S Leroith D 2012 Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Research 14 R8. (doi:10.1186/bcr3089)
17. Gatenby RA & Gillies RJ 2004 Why do cancers have high aerobic glycolysis? Nature Reviews. Cancer 4 891-899. (doi:10.1038/nrc1478)
18. Gillies RJ, Robey I & Gatenby RA 2008 Causes and consequences of increased glucose metabolism of cancers. Journal of Nuclear Medicine 49 (Suppl 2) 24S-42S. (doi:10.2967/jnumed.107.047258)
19. Glozak MA & Seto E 2007 Histone deacetylases and cancer. Oncogene 26 5420-5432. (doi:10.1038/sj.onc.1210610)
20. Grimes CA & Jope RS 2001 The multifaceted roles of glycogen synthase kinase 3b in cellular signaling. Progress in Neurobiology 65 391-426. (doi:10.1016/S0301-0082(01)00011-9)
21. Gupta-Elera G, Garrett AR, Robison RA & O'Neill KL 2012 The role of oxidative stress in prostate cancer. European Journal of Cancer Prevention 21 155-162. (doi:10.1097/CEJ.0b013e32834a8002)
22. He Y, Franco OE, Jiang M, Williams K, Love HD, Coleman IM, Nelson PS & Hayward SW 2007 Tissue-specific consequences of cyclin D1 over-expression in prostate cancer progression. Cancer Research 67 8188-8197. (doi:10.1158/0008-5472.CAN-07-0418)
23. Henriksen EJ 2010 Dysregulation of glycogen synthase kinase-3 in skeletal muscle and the etiology of insulin resistance and type 2 diabetes. Current Diabetes Reviews 6 285-293. (doi:10.2174/ 157339910793360888)
24. Kabra DG, Gupta J & Tikoo K 2009 Insulin induced alteration in post-translational modifications of histone H3 under a hyperglycemic condition in L6 skeletal muscle myoblasts. Biochimica et Biophysica Acta 1792 574-583. (doi:10.1016/j.bbadis.2009.03.003)
25. Kurdistani SK 2007 Histone modifications as markers of cancer prognosis: a cellular view. British Journal of Cancer 97 1-5. (doi:10.1038/sj.bjc.6603844)
26. Lai A, Sarcevic B, Prall OW & Sutherland RL 2001 Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1). Journal of Biological Chemistry 276 25823-25833. (doi:10.1074/jbc.M100925200)
27. Laudanski P, Swiatecka J, Kovalchuk O & Wolczynski S 2003 Expression of GLUT1 gene in breast cancer cell lines MCF-7 and MDA-MB-231. Ginekologia Polska 74 782-785.
28. Liao S, Li J, Wei W, Wang L, Zhang Y, Wang C & Sun S 2011 Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pacific Journal of Cancer Prevention 12 1061-1065.
29. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG & Hung MC 2000 B-Catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. PNAS 97 4262-4266.(doi:10.1073/pnas.060025397)
30. Liu H, Ma Q & Li J 2011a High glucose promotes cell proliferation and enhances GDNF and RET expressioninpancreatic cancercells. Molecular and Cellular Biochemistry 347 95-101. (doi:10.1007/s11010-010-0617-0)
31. Liu S, Li Y, Lin T, Fan X, Liang Y & Heemann U 2011b High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Research and Clinical Practice 91 177-182. (doi:10.1016/j.diabres.2010.11.009)
32. Luo J 2009 Glycogen synthase kinase 3b (GSK3b) in tumorigenesis and cancer chemotherapy. Cancer Letters 273 194-200. (doi:10.1016/ j.canlet.2008.05.045)
33. Martindale JL & Holbrook NJ 2002 Cellular response to oxidative stress: signaling for suicide and survival. Journal of Cellular Physiology 192 1-15. (doi:10.1002/jcp.10119)
34. Mates JM & Sanchez-Jimenez FM 2000 Role of reactive oxygen species in apoptosis: implications for cancer therapy. International Journal of Biochemistry & Cell Biology 32 157-170. (doi:10.1016/S1357-2725(99)00088-6)
35. Mathew OP, Ranganna K & Yatsu FM 2010 Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells. Biomedicine & Pharmacotherapy 64 733-740. (doi:10.1016/j.biopha.2010.09.017)
36. Medunjanin S, Hermani A, De Servi B, Grisouard J, Rincke G & Mayer D 2005 Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor a and is involved in the regulation of receptor activity. Journal of Biological Chemistry 280 33006-33014. (doi:10.1074/ jbc.M506758200)
37. Monks TJ, Xie R, Tikoo K & Lau SS 2006 ROS-induced histone modifications and their role in cell survival and cell death. Drug Metabolism Reviews 38 755-767. (doi:10.1080/03602530600959649)
38. Musgrove EA 2006 Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 24 13-19. (doi:10.1080/ 08977190500361812)
39. Nakagami H, Morishita R, Yamamoto K, Yoshimura SI, Taniyama Y, Aoki M, Matsubara H, Kim S, Kaneda Y & Ogihara T 2001 Phosphorylation of p38 mitogen-activated protein kinase downstream of Bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells. Diabetes 50 1472-1481. (doi:10.2337/diabetes.50.6.1472)
40. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L & Henry RR 2000 Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 49 263-271. (doi:10.2337/ diabetes.49.2.263)
41. O'Mahony F, Razandi M, Pedram A, Harvey BJ & Levin ER 2012 Estrogen modulates metabolic pathway adaptation to available glucose in breast cancer cells. Molecular Endocrinology 26 2058-2070. (doi:10.1210/ me.2012-1191)
42. Ortmann J, Veit M, Zingg S, Di Santo S, Traupe T, Yang Z, Volzmann J, Dubey RK, Christen S & Baumgartner I 2011 Estrogen receptor-a but not -b or GPER inhibits high glucose-induced human VSMC proliferation: potential role of ROS and ERK. Journal of Clinical Endocrinology and Metabolism 96 220-228. (doi:10.1210/jc.2010-0943)
43. Papa V & Belfiore A 1996 Insulin receptors in breast cancer: biological and clinical role. Journal of Endocrinological Investigation 19 324-333.
44. Papa V, Costantino A & Belfiore A 1997 Insulin receptor what role in breast cancer? Trends in Endocrinology and Metabolism 8 306-312. (doi:10.1016/S1043-2760(97)00114-8)
45. Patel S, Doble BW, MacAulay K, Sinclair EM, Drucker DJ & Woodgett JR 2008 Tissue-specific role of glycogen synthase kinase 3b in glucose homeostasis and insulin action. Molecular and Cellular Biology 28 6314-6328. (doi:10.1128/MCB.00763-08)
46. Pelicano H, Carney D & Huang P 2004 ROS stress in cancer cells and therapeutic implications. Drug Resistance Updates 7 97-110. (doi:10.1016/j.drup.2004.01.004)
47. Perkins ND 2004 NF-kB: tumor promoter or suppressor? Trends in Cell Biology 14 64-69. (doi:10.1016/j.tcb.2003.12.004)
48. Rahman I 2002 Oxidative stress, transcription factors and chromatin remodelling in lung inflammation. Biochemical Pharmacology 64 935-942. (doi:10.1016/S0006-2952(02)01153-X)
49. Rajendrasozhan S, Yao H & Rahman I 2009 Current perspectives on role of chromatin modifications and deacetylases in lung inflammation in COPD. COPD 6 291-297. (doi:10.1080/15412550903049132)
50. Rasola A, Sciacovelli M, Chiara F, Pantic B, Brusilow WS & Bernardi P 2010 Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. PNAS 107 726-731. (doi:10.1073/pnas.0912742107)
51. Razidlo GL, Kortum RL, Haferbier JL & Lewis RE 2004 Phosphorylation regulates KSR1 stability, ERK activation, and cell proliferation. Journal of Biological Chemistry 279 47808-47814. (doi:10.1074/jbc. M406395200)
52. Ryan KM, Ernst MK, Rice NR & Vousden KH 2000 Role of NF-kB in p53-mediated programmed cell death. Nature 404 892-897. (doi:10.1038/35009130)
53. Seoane M, Mosquera-Miguel A, Gonzalez T, Fraga M, Salas A & Costoya JA 2011 The mitochondrial genome is a "genetic sanctuary" during the oncogenic process. PLoS ONE 6 e23327. (doi:10.1371/journal.pone. 0023327)
54. Shin H, Lee YS & Lee YC 2011 Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer. Oncology Reports 27 1111-1115. (doi:10.3892/or.2011.1585)
55. Suh S & Kim KW 2011 Diabetes and cancer: is diabetes causally related to cancer? Diabetes & Metabolism Journal 35 193-198. (doi:10.4093/ dmj.2011.35.3.193)
56. Susztak K, Raff AC, Schiffer M & Bottinger EP 2006 Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55 225-233. (doi:10.2337/diabetes.55.01.06.db05-0894)
57. Sutherland RL & Musgrove EA 2002 Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Research 4 14-17. (doi:10.1186/bcr411)
58. Takahashi-Yanaga F & Sasaguri T 2008 GSK-3b regulates cyclin D1 expression: a new target for chemotherapy. Cellular Signalling 20 581-589. (doi:10.1016/j.cellsig.2007.10.018)
59. Tamir S, Izrael S & Vaya J 2002 The effect of oxidative stress on ERa and ERb expression. Journal of Steroid Biochemistry and Molecular Biology 81 327-332. (doi:10.1016/S0960-0760(02)00115-2)
60. Tan H, Zhong Y & Pan Z 2009 Autocrine regulation of cell proliferation by estrogen receptor-a in estrogen receptor-a-positive breast cancer cell lines. BMC Cancer 9 31. (doi:10.1186/1471-2407-9-31)
61. Thomson S, Clayton AL, Hazzalin CA, Rose S, Barratt MJ & Mahadevan LC 1999 The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO Journal 18 4779-4793. (doi:10.1093/emboj/18.17.4779)
62. Thornton TM & Rincon M 2009 Non-classical p38 map kinase functions: cell cycle checkpoints and survival. International Journal of Biological Sciences 5 44-51. (doi:10.7150/ijbs.5.44)
63. Tikoo K, Tripathi DN, Kabra DG, Sharma V & Gaikwad AB 2007 Intermittent fasting prevents the progression of type I diabetic nephropathy in rats and changes the expression of Sir2 and p53. FEBS Letters 581 1071-1078. (doi:10.1016/j.febslet.2007.02.006)
64. Tikoo K, Meena RL, Kabra DG & Gaikwad AB 2008 Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. British Journal of Pharmacology 153 1225-1231. (doi:10.1038/sj.bjp.0707666)
65. Villarreal-Garza C, Shaw-Dulin R, Lara-Medina F, Bacon L, Rivera D, Urzua L, Aguila C, Ramirez-Morales R, Santamaria J, Bargallo E et al. 2012 Impact of diabetes and hyperglycemia on survival in advanced breast cancer patients. Experimental Diabetes Research 2012 732027. (doi:10.1155/2012/732027)
66. Vinodhkumar R, Song YS & Devaki T 2008 Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. Biomedicine & Pharmacotherapy 62 85-93. (doi:10.1016/j.biopha.2007.06.002)
67. Weichhaus M, Broom J, Wahle K & Bermano G 2012 A novel role for insulin resistance in the connection between obesity and postmeno-pausal breast cancer. International Journal of Oncology 41 745-752.
68. Weinstein D, Simon M, Yehezkel E, Laron Z & Werner H 2009 Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes/Metabolism Research and Reviews 25 41-49. (doi:10.1002/dmrr.912)
69. Weitsman GE, Weebadda W, Ung K & Murphy LC 2009 Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor a. Breast Cancer Research Treatment 118 269-279. (doi:10.1007/s10549-008-0221-0)
70. Whyte J, Bergin O, Bianchi A, McNally S & Martin F 2009 Key signaling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Research 11 209. (doi:10.1186/bcr2361)
71. Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa MZ, Catane R & Kaufman B 2006 Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. European Journal of Cancer 42 1077-1082. (doi:10.1016/j.ejca.2006.01.027)
72. Xue F & Michels KB 2007 Diabetes, metabolic syndrome, and breast cancer:a review of the current evidence. American Journal of Clinical Nutrition 86 s823-s835.
73. Zeng L, Biernacka KM, Holly JM, Jarrett C, Morrison AA, Morgan A, Winters ZE, Foulstone EJ, Shield JP & Perks CM 2010 Hyperglycemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocrine-Related Cancer 17 539-551. (doi:10.1677/ERC-09-0221)